Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Japan Spinout RaQualia Cuts Another Deal With Korea's CJ CheilJedang

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In a follow-up to a memorandum of understanding signed in 2010, CJ CheilJedang Corp. signed an agreement with RaQualia Pharm Inc. for exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 partial agonist (RQ-0010) in South Korea, China, Taiwan, India and Southeast Asia

You may also be interested in...



Pfizer Japan Spin-out RaQualia Looks To Find Its Niche

Although RaQualia narrowly avoided the brunt of recent economic crises, timing still matters when finding a licensor, CEO says.

Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence

The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.

Korea's CJ CheilJedang and Japan's RaQualia Pharma Partner For Gastrointestinal Therapies

SEOUL - South Korea's CJ CheilJedang signed a memorandum of understanding and subsequently a licensing agreement with Japan's RaQualia Pharma to establish a strategic alliance for the latter's innovative gastrointestinal therapies

Related Content

UsernamePublicRestriction

Register

SC078908

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel